TriangleBrentuximab Vedotin (NCT04561206)
Brentuximab Vedotin trial for Relapsed Classic Hodgkin Lymphoma (NCT04561206). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with classical Hodgkin lymphoma that returned or resisted one treatment line, who cannot have or decline autologous stem-cell transplantation. Prior brentuximab or checkpoint treatment has response restrictions.
The idea: combine brentuximab vedotin and nivolumab infusions every three weeks, for up to sixteen cycles. Brentuximab delivers a toxin to CD30-bearing cells; nivolumab blocks PD-1 to support immune attack. Researchers assess whether early complete responders maintain cancer control without transplant consolidation.
This phase 2 study plans 31 patients. Alex Herrera leads City of Hope's study at five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.